Richard E. Gilbert


Scientist, Keenan Research Centre for Biomedical Science


Richard Gilbert is Professor of Medicine at the University of Toronto, Canada Research Chair in Diabetes Complications and Head of the Division of Endocrinology at St. Michael’s Hospital in Toronto. His major interests are in the treatment and prevention of diabetic complications with an emphasis on nephropathy and heart failure. Dr. Gilbert has published over 220 peer-reviewed manuscripts, has numerous patents and co-founded Fibrotech, a biotechnology company that has brought novel anti-fibrotic therapies from the bench to early phase human trials. He is currently a member of the editorial board of Diabetes. Current research projects relate to the use of new therapies for the prevention and treatment of chronic kidney disease and heart failure. In addition to his bench research, Dr. Gilbert is actively involved in teaching and knowledge translation. He currently heads Guidelines Committees for the management of hypertension in diabetes.

Recent Publications

  1. Gilbert, RE. Diabetic kidney disease 2.0: the treatment paradigm shifts. Lancet Diabetes Endocrinol. 2019; :. doi: 10.1016/S2213-8587(19)30253-0. PubMed PMID:31495650 .
  2. Verma, S, Mazer, CD, Yan, AT, Mason, T, Garg, V, Teoh, H et al.. Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation. 2019; :. doi: 10.1161/CIRCULATIONAHA.119.042375. PubMed PMID:31434508 .
  3. Bellin, AR, Zhang, Y, Thai, K, Rosenblum, ND, Cullen-McEwen, LA, Bertram, JF et al.. Impaired SIRT1 activity leads to diminution in glomerular endowment without accelerating age-associated GFR decline. Physiol Rep. 2019;7 (9):e14044. doi: 10.14814/phy2.14044. PubMed PMID:31087539 PubMed Central PMC6513772.
  4. Gilbert, RE, Thorpe, KE. Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: A meta-analysis of cardiovascular outcome trials. Diabetes Obes Metab. 2019;21 (8):1996-2000. doi: 10.1111/dom.13754. PubMed PMID:31050116 .
  5. Connelly, KA, Zhang, Y, Visram, A, Advani, A, Batchu, SN, Desjardins, JF et al.. Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction. JACC Basic Transl Sci. 2019;4 (1):27-37. doi: 10.1016/j.jacbts.2018.11.010. PubMed PMID:30847416 PubMed Central PMC6390677.
  6. Gilbert, RE, Connelly, KA. Reduction in the incidence of myocardial infarction with sodium-glucose linked cotransporter-2 inhibitors: evident and plausible. Cardiovasc Diabetol. 2019;18 (1):6. doi: 10.1186/s12933-019-0812-6. PubMed PMID:30634959 PubMed Central PMC6329062.
  7. Zhang, Y, Thai, K, Kepecs, DM, Winer, D, Gilbert, RE. Reversing CXCL10 Deficiency Ameliorates Kidney Disease in Diabetic Mice. Am. J. Pathol. 2018;188 (12):2763-2773. doi: 10.1016/j.ajpath.2018.08.017. PubMed PMID:30273603 .
  8. Zhang, Y, Thai, K, Jin, T, Woo, M, Gilbert, RE. SIRT1 activation attenuates α cell hyperplasia, hyperglucagonaemia and hyperglycaemia in STZ-diabetic mice. Sci Rep. 2018;8 (1):13972. doi: 10.1038/s41598-018-32351-z. PubMed PMID:30228292 PubMed Central PMC6143559.
  9. Connelly, KA, Zhang, Y, Desjardins, JF, Thai, K, Gilbert, RE. Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction. Cardiovasc Diabetol. 2018;17 (1):99. doi: 10.1186/s12933-018-0741-9. PubMed PMID:29981571 PubMed Central PMC6035399.
  10. Bugyei-Twum, A, Ford, C, Civitarese, R, Seegobin, J, Advani, SL, Desjardins, JF et al.. Sirtuin 1 activation attenuates cardiac fibrosis in a rodent pressure overload model by modifying Smad2/3 transactivation. Cardiovasc. Res. 2018;114 (12):1629-1641. doi: 10.1093/cvr/cvy131. PubMed PMID:29800064 PubMed Central PMC6148332.
Search PubMed

Affiliations & Other Activities

  • Staff Physician, Department of Medicine, Division of Endocrinology, St. Michael’s Hospital
  • Professor, Department of Medicine, University of Toronto